FIELD: medicine; chemistry.
SUBSTANCE: invention relates to use of duocarmicin conjugates of antibody-drug (ADC) of formula (II) for treating human solid tumours expressing HER2, wherein said human solid tumour expressing HER2 is HER2 IHC 2+ or 1.
EFFECT: advantage of conjugates of the declared invention consists in possibility of their application for treatment of thrice negative breast cancer (TNBC).
8 cl, 12 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WITH DUOCARMICIN USED FOR TREATING ENDOMETRIAL CANCER | 2015 |
|
RU2686085C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
